Medicine and Dentistry
Patient
100%
Pulmonary Hypertension
74%
COVID-19
23%
Health
23%
Inpatient
21%
Survival
19%
Symptom
17%
Quality of Life
15%
Polycyclic Aromatic Hydrocarbon
15%
Therapeutic Procedure
14%
Chronic Thromboembolic Pulmonary Hypertension
13%
Connective Tissue Disease
12%
T Cell
11%
T-Helper Cell
11%
Follow up
10%
Bruton Tyrosine Kinase
9%
Marker
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Brain Natriuretic Peptide
7%
Minimal Clinically Important Difference
7%
Six Minute Walk Test
7%
Cytokine
7%
Tumor Necrosis Factor
7%
Adult
6%
Diagnosis
6%
Plasma
6%
B Cell
5%
Lung Injury
5%
B Cell Activation
5%
Persistent Truncus Arteriosus
5%
Pharmacology, Toxicology and Pharmaceutical Science
Tocilizumab
23%
Riociguat
23%
Chronic Thromboembolic Pulmonary Hypertension
14%
Adverse Event
11%
Interleukin 6
7%
Pneumonia
5%
Pulmonary Hypertension
5%
Heart Failure
5%
Drug
5%
Survival
5%
Death
5%
Mortality
5%
Immunology and Microbiology
Health
23%
Life
15%
Survival
11%
Connective Tissue
10%
CXCL9
9%
Classification
5%